But the overall survival benefit in prostate cancer is still driven by HRR mutations.

Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.

AbbVie follows Gilead in throwing Xilio a lifeline.

The deal isn’t done, but would be Merck’s biggest oncology buy.

Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.

Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.